BCAN applauds the U.S. Food and Drug Administration (FDA) for approving Opdivo for use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containingor have disease progression within 12 months of neoadjuvant or treatment with platinum-containing .
“Althoughis the 5th most commonly diagnosed cancer in the United States, it is only recently that we are starting to see new treatments being approved to help patients with this disease,” according to Andrea Maddox-Smith, CEO of BCAN. “The FDA’s approval of Opdivo offers a much-needed treatment option for the community. We are grateful that the FDA moved swiftly to review and approve Opdivo and are very thankful to those patients and families who participated in the clinical trials for this drug. We are hopeful that there will be more new therapies approved for all stages of in the near future.”
Read more about Opdivo here.
Read BCAN press release here.